Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$0.17
-41.7%
$4.79
$4.86
$37.50
$1.01M1.55467,323 shs18.30 million shs
NIMU
Non-Invasive Monitoring Systems
$0.01
$0.01
$0.00
$0.04
$1.86M0.66670 shsN/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
$0.00
$0.00
$0.00
N/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
$0.00
$2.91
$82.80
$1.90M2.031,362 shs6,500 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nuwellis, Inc. stock logo
CHFS
Nuwellis
+14.64%+10.98%-29.51%-41.03%-93.55%
NIMU
Non-Invasive Monitoring Systems
0.00%+1.69%+1.69%-0.83%-25.47%
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
0.00%0.00%0.00%0.00%-99.93%
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/AN/AN/AN/A
NIMU
Non-Invasive Monitoring Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/AN/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/A
NIMU
Non-Invasive Monitoring Systems
N/AN/AN/AN/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nuwellis, Inc. stock logo
CHFS
Nuwellis
$5.51M0.18N/AN/A$12.79 per share0.01
NIMU
Non-Invasive Monitoring Systems
N/AN/AN/AN/AN/AN/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
$610K0.00N/A0.08$341.84 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nuwellis, Inc. stock logo
CHFS
Nuwellis
-$18.11M-$279.28N/AN/AN/A-254.26%-173.61%-131.01%N/A
NIMU
Non-Invasive Monitoring Systems
-$200KN/A0.00N/AN/AN/A-251.56%N/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/A0.00N/AN/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
-$81.15MN/A0.00N/AN/A-668.58%-163.22%-52.10%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/AN/AN/AN/AN/A
NIMU
Non-Invasive Monitoring Systems
N/AN/AN/AN/AN/A
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nuwellis, Inc. stock logo
CHFS
Nuwellis
N/A
6.87
5.97
NIMU
Non-Invasive Monitoring Systems
N/A
0.36
0.36
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
0.05
1.17
1.07

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Nuwellis, Inc. stock logo
CHFS
Nuwellis
65.06%
NIMU
Non-Invasive Monitoring Systems
0.12%
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
N/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Nuwellis, Inc. stock logo
CHFS
Nuwellis
666.04 millionN/ANot Optionable
NIMU
Non-Invasive Monitoring Systems
3154.81 million110.23 millionNot Optionable
Nexeon Medsystems Inc stock logo
NXNN
Nexeon Medsystems
62N/AN/ANot Optionable
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
43354,000N/ANot Optionable

NIMU, NXNN, CHFS, and RSLSD Headlines

SourceHeadline
Insider Selling: STANKOVICH THOMAS, ReShape Lifesciences Inc. [RSLS] Chief Financial Officer divested 106 sharesInsider Selling: STANKOVICH THOMAS, ReShape Lifesciences Inc. [RSLS] Chief Financial Officer divested 106 shares
knoxdaily.com - November 2 at 5:17 PM
ReShape Lifesciences (NASDAQ: RSLS) up 60% - But why in the name of….?ReShape Lifesciences (NASDAQ: RSLS) up 60% - But why in the name of….?
dhakatribune.com - October 27 at 2:21 PM
ReShape Lifesciences Inc. [RSLS] Shares Fall Approximately -98.23% Over the YearReShape Lifesciences Inc. [RSLS] Shares Fall Approximately -98.23% Over the Year
knoxdaily.com - October 12 at 3:16 PM
ReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive License Agreement With Biorad Medisys for Obalon Gastric Balloon SystemReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive License Agreement With Biorad Medisys for Obalon Gastric Balloon System
finanznachrichten.de - September 21 at 10:10 AM
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon SystemReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
finance.yahoo.com - September 21 at 10:10 AM
Recent Insider Activity Could Benefit ReShape Lifesciences Inc. (RSLS)Recent Insider Activity Could Benefit ReShape Lifesciences Inc. (RSLS)
knoxdaily.com - June 29 at 11:06 PM
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
finance.yahoo.com - June 26 at 5:52 PM
Potential Price Increase for ReShape Lifesciences Inc. (RSLS) After Recent Insider ActivityPotential Price Increase for ReShape Lifesciences Inc. (RSLS) After Recent Insider Activity
knoxdaily.com - June 19 at 7:45 PM
ReShape Lifesciences® to Participate in Investor and Industry Conferences in JuneReShape Lifesciences® to Participate in Investor and Industry Conferences in June
finance.yahoo.com - June 14 at 8:57 AM
ReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2023 Earnings Call TranscriptReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2023 Earnings Call Transcript
insidermonkey.com - May 17 at 5:09 PM
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 DiabetesReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
markets.buffalonews.com - April 27 at 9:54 AM
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-MarketReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
finance.yahoo.com - April 20 at 10:16 AM
ReShape Lifesciences(R) Receives Notice of Allowance for U.S. Patent Related to its Obalon(R) Balloon SystemReShape Lifesciences(R) Receives Notice of Allowance for U.S. Patent Related to its Obalon(R) Balloon System
marketwatch.com - April 12 at 3:13 PM
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon SystemReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
finance.yahoo.com - April 11 at 9:04 AM
ReShape Lifesciences postpones earnings releaseReShape Lifesciences postpones earnings release
seekingalpha.com - March 31 at 4:37 PM
Earnings Outlook For Reshape LifesciencesEarnings Outlook For Reshape Lifesciences
msn.com - March 28 at 2:08 PM
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public OfferingReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
benzinga.com - February 8 at 12:59 PM
Why Is Reshape Lifesciences (RSLS) Stock Up 136% Today?Why Is Reshape Lifesciences (RSLS) Stock Up 136% Today?
msn.com - February 3 at 8:23 AM
ReShape Lifesciences Inc. (RSLS) Q3 2022 Earnings Call TranscriptReShape Lifesciences Inc. (RSLS) Q3 2022 Earnings Call Transcript
seekingalpha.com - November 14 at 1:46 PM
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
yahoo.com - November 14 at 8:46 AM
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device ...ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device ...
bakersfield.com - November 5 at 11:22 PM
ReShape Lifesciences to Present at the Q4 Investor SummitReShape Lifesciences to Present at the Q4 Investor Summit
benzinga.com - November 2 at 7:19 PM
ReShape Lifesciences(TM) Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation(TM) DeviceReShape Lifesciences(TM) Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device
stockhouse.com - September 24 at 1:07 PM
ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ DeviceReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
nz.finance.yahoo.com - September 22 at 8:49 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Nuwellis logo

Nuwellis

NASDAQ:CHFS
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Non-Invasive Monitoring Systems

OTCMKTS:NIMU
Non-Invasive Monitoring Systems, Inc. does not have significant operations. Previously, it was involved in the research, development, manufacture, marketing, and sale of non-invasive, motorized, and whole body periodic acceleration platforms. The company was incorporated in 1980 and is based in Miami, Florida.
Nexeon Medsystems logo

Nexeon Medsystems

OTCMKTS:NXNN
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
ReShape Lifesciences logo

ReShape Lifesciences

OTCMKTS:RSLSD
ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.